444 related articles for article (PubMed ID: 26325034)
1. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.
Buchbinder E; Hodi FS
J Clin Invest; 2015 Sep; 125(9):3377-83. PubMed ID: 26325034
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Buchbinder EI; McDermott DF
Clin Ther; 2015 Apr; 37(4):755-63. PubMed ID: 25746738
[TBL] [Abstract][Full Text] [Related]
3. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
4. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
Qian JM; Yu JB; Kluger HM; Chiang VL
Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
[TBL] [Abstract][Full Text] [Related]
5. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
Hailemichael Y; Woods A; Fu T; He Q; Nielsen MC; Hasan F; Roszik J; Xiao Z; Vianden C; Khong H; Singh M; Sharma M; Faak F; Moore D; Dai Z; Anthony SM; Schluns KS; Sharma P; Engelhard VH; Overwijk WW
J Clin Invest; 2018 Apr; 128(4):1338-1354. PubMed ID: 29480817
[TBL] [Abstract][Full Text] [Related]
6. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic use of anti-CTLA-4 antibodies.
Blank CU; Enk A
Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for malignant melanoma.
Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F
Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic T-lymphocyte-associated antigen-4.
Salama AK; Hodi FS
Clin Cancer Res; 2011 Jul; 17(14):4622-8. PubMed ID: 21467163
[TBL] [Abstract][Full Text] [Related]
11. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
Simeone E; Ascierto PA
J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
[TBL] [Abstract][Full Text] [Related]
13. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
14. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
Blank CU
Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
[TBL] [Abstract][Full Text] [Related]
15. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
Bronstein Y; Ng CS; Hwu P; Hwu WJ
AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
17. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
Chapuis AG; Roberts IM; Thompson JA; Margolin KA; Bhatia S; Lee SM; Sloan HL; Lai IP; Farrar EA; Wagener F; Shibuya KC; Cao J; Wolchok JD; Greenberg PD; Yee C
J Clin Oncol; 2016 Nov; 34(31):3787-3795. PubMed ID: 27269940
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoints and their inhibition in cancer and infectious diseases.
Dyck L; Mills KHG
Eur J Immunol; 2017 May; 47(5):765-779. PubMed ID: 28393361
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; Vesely MD; Lam SS; Korman AJ; Allison JP; Freeman GJ; Sharpe AH; Pearce EL; Schumacher TN; Aebersold R; Rammensee HG; Melief CJ; Mardis ER; Gillanders WE; Artyomov MN; Schreiber RD
Nature; 2014 Nov; 515(7528):577-81. PubMed ID: 25428507
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.
Elia AR; Caputo S; Bellone M
Front Immunol; 2018; 9():1786. PubMed ID: 30108594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]